Physician profile
Vijay Halari
NPI 1487006862
$11,065.66
in general payments reported to CMS, 2019-2025
36 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.74 · 2020: $1,629 · 2021: $1,860 · 2022: $1,309 · 2023: $2,086 · 2024: $2,236 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,253.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,066.63 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,945.63 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,261.25 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,012.29 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Glaxosmithkline, LLC. | $828.72 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $733.63 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $621.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.20 | 2020-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $266.43 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $181.26 | 2020-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $159.35 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $150.00 | 2023-2025 | Quviviq, Quviviq |
| Amarin Pharma, INC. | $144.21 | 2020-2023 | |
| Daiichi Sankyo INC. | $135.79 | 2022-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $133.12 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $126.37 | 2020 | |
| Exact Sciences Corporation | $122.25 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $112.99 | 2020-2025 | Belsomra, Steglatro, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $97.55 | 2020-2024 | Austedo Xr, Austedo |
| Sanofi Pasteur INC. | $63.23 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $54.55 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $43.14 | 2021 | |
| Astellas Pharma US INC | $40.04 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.26 | 2022-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $27.01 | 2022 | |
| Avanir Pharmaceuticals, INC. | $24.46 | 2022 | |
| Phadia US INC. | $19.93 | 2023 | Immunocap |
| Boston Scientific Corporation | $18.33 | 2025 | General - Pain Management |
| Xeris Pharmaceuticals, INC. | $17.77 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $17.06 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $16.94 | 2023 | Heplisav-B |
| Vanda Pharmaceuticals INC. | $15.55 | 2025 | Fanapt |
| Redhill Biopharma INC. | $13.74 | 2023 | Talicia |
| Ibsa Pharma INC. | $13.51 | 2023 | Tirosint, Licart |
| Medtronic, INC. | $13.30 | 2024 | Closurefast |
| Gilead Sciences, INC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Halari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.